Dataset Information

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.

ABSTRACT: Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72'250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative incidence rose from 2.3% in June 2020 to 12.2% in mid-December 2020. A follow-up health survey indicated that about 10% of patients infected with wildtype SARS-CoV-2 sustained some symptoms at least twelve months post COVID-19. Crucially, we found no evidence of a difference in long-term complications between those whose infection was symptomatic and those with asymptomatic acute infection. The cohort of asymptomatic SARS-CoV-2-infected subjects represents a resource for the study of chronic and possibly unexpected sequelae.

SUBMITTER: Emmenegger M

PROVIDER: S-EPMC9811913 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.

Emmenegger Marc M De Cecco Elena E Lamparter David D Jacquat Raphaël P B RPB Riou Julien J Menges Dominik D Ballouz Tala T Ebner Daniel D Schneider Matthias M MM Morales Itzel Condado IC Doğançay Berre B Guo Jingjing J Wiedmer Anne A Domange Julie J Imeri Marigona M Moos Rita R Zografou Chryssa C Batkitar Leyla L Madrigal Lidia L Schneider Dezirae D Trevisan Chiara C Gonzalez-Guerra Andres A Carrella Alessandra A Dubach Irina L IL Xu Catherine K CK Meisl Georg G Kosmoliaptsis Vasilis V Malinauskas Tomas T Burgess-Brown Nicola N Owens Ray R Hatch Stephanie S Mongkolsapaya Juthathip J Screaton Gavin R GR Schubert Katharina K Huck John D JD Liu Feimei F Pojer Florence F Lau Kelvin K Hacker David D Probst-Müller Elsbeth E Cervia Carlo C Nilsson Jakob J Boyman Onur O Saleh Lanja L Spanaus Katharina K von Eckardstein Arnold A Schaer Dominik J DJ Ban Nenad N Tsai Ching-Ju CJ Marino Jacopo J Schertler Gebhard F X GFX Ebert Nadine N Thiel Volker V Gottschalk Jochen J Frey Beat M BM Reimann Regina R RR Hornemann Simone S Ring Aaron M AM Knowles Tuomas P J TPJ Puhan Milo A MA Althaus Christian L CL Xenarios Ioannis I Stuart David I DI Aguzzi Adriano A

iScience 20230104 2

Effective public health measures against SARS-CoV-2 require granular knowledge of population-level immune responses. We developed a Tripartite Automated Blood Immunoassay (TRABI) to assess the IgG response against three SARS-CoV-2 proteins. We used TRABI for continuous seromonitoring of hospital patients and blood donors (n = 72'250) in the canton of Zurich from December 2019 to December 2020 (pre-vaccine period). We found that antibodies waned with a half-life of 75 days, whereas the cumulative ...[more]

PMID: 36619367

Similar Datasets

Project description:IntroductionSARS-CoV-2 seroprevalence studies are currently being recommended and implemented in many countries. Forming part of the COVID-19 monitoring and evaluation plan of the Catalan Government Health Department, our network aims to initiate a primary healthcare sentinel monitoring system as a surrogate of SARS-CoV-2 exposure in the Barcelona Metropolitan Area.Methods and analysisThe seroCAP is a serial cross-sectional study, which will be performed in the Barcelona Metropolitan Area to estimate antibodies against SARS-CoV-2. From February 2021 to March 2022, the detection of serum IgG antibodies against SARS-CoV-2 trimeric spike protein will be performed on a monthly basis in blood samples collected for diverse clinical purposes in three reference hospitals from the three Barcelona healthcare areas (BCN areas). The samples (n=2588/month) will be from patients attended by 30 primary healthcare teams at 30 basic healthcare areas (BHA). A lab software algorithm will systematically select the samples by age and sex. Seroprevalence will be estimated and monitored by age, sex, BCN area and BHA. Descriptive and cluster analysis of the characteristics and distribution of SARS-CoV-2 infections will be performed. Sociodemographic, socioeconomic and morbidity-associated factors will be determined using logistic regression. We will explore the association between seroprevalence, SARS-CoV-2 confirmed cases and the implemented measures using interrupted time series analysis.Ethics and disseminationEthical approval was obtained from the University Institute Foundation for Primary Health Care Research Jordi Gol i Gurina ethics committee. An informed consent is not required regarding the approval of the secondary use of biological samples within the framework of the COVID-19 pandemic. A report will be generated quarterly. The final analysis, conclusions and recommendations will be shared with the stakeholders and communicated to the general public. Manuscripts resulting from the network will be submitted for publication in peer-reviewed journals.

Dataset Information

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.

Publications

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets